These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 14416030)
1. The pharmacological evaluation of monoamine oxidase inhibitors. LESSIN AW Biochem Pharmacol; 1959 Nov; 2():290-8. PubMed ID: 14416030 [No Abstract] [Full Text] [Related]
2. Significance of monoamine oxidase inhibition for the pharmacological and clinical effects of hydrazine derivatives. PLETSCHER A Ann N Y Acad Sci; 1959 Sep; 80():1039-45. PubMed ID: 14433482 [No Abstract] [Full Text] [Related]
3. Biochemical and pharmacological effects of the monoamine oxidase inhibitors, iproniazid, 1-phenyl-2-hydrazinopropane (JB 516) and 1-phenyl-3-hydrazinobutane (JB 835). SPECTOR S; SHORE PA; BRODIE BB J Pharmacol Exp Ther; 1960 Jan; 128():15-21. PubMed ID: 13833205 [No Abstract] [Full Text] [Related]
4. Studies on monoamine oxidase. 2: p-Methylphenyl hydrazine, a potent and selective monoamine oxidase inhibitor. ARAI A Jpn J Pharmacol; 1960 Mar; 9():159-68. PubMed ID: 13683948 [No Abstract] [Full Text] [Related]
5. Anticonvulsant properties of monoamine oxidase inhibitors. PROCKOP DJ; SHORE PA; BRODIE BB Ann N Y Acad Sci; 1959 Sep; 80():643-51. PubMed ID: 14434994 [No Abstract] [Full Text] [Related]
6. Histochemical demonstration in rat of monoamine oxidase inhibition of beta-phenyl-isopropyl hydrazine. MUSTAKALLIO KK; LEVONEN E; RAEKALLIO J Science; 1961 Aug; 134(3475):344. PubMed ID: 13727138 [TBL] [Abstract][Full Text] [Related]
7. Theoretic background of therapy with monoamine oxidase inhibitors in cardiology. ZBINDEN G Am J Cardiol; 1960 Dec; 6():1121-4. PubMed ID: 13788034 [No Abstract] [Full Text] [Related]
8. Reversal of the reserpine-induced depletion of brain serotonin by a monoamine oxidase inhibitor. CANAL N; MAFFEI-FACCIOLI A J Neurochem; 1959 Dec; 5():99-100. PubMed ID: 13807360 [No Abstract] [Full Text] [Related]
9. The route of administration of some hydrazine compounds as a determinant of brain and liver monoamine oxidase inhibition. HORITA A Toxicol Appl Pharmacol; 1961 Jul; 3():474-80. PubMed ID: 13715854 [No Abstract] [Full Text] [Related]
10. Specific liver and brain monoamine oxidase inhibition by alkyl- and arylalkylhydrazines. HORITA A; McGRATH WR Proc Soc Exp Biol Med; 1960 Apr; 103():753-7. PubMed ID: 14403108 [No Abstract] [Full Text] [Related]
11. In vivo monoamine oxidase inhibition measured by potentiation of tryptamine convulsions in rats. TEDESCHI DH; TEDESCHI RE; FELLOWS EJ Proc Soc Exp Biol Med; 1960 Apr; 103():680-2. PubMed ID: 13837257 [No Abstract] [Full Text] [Related]
12. [Pharmacological properties of a new inhibitor of monoamine oxidase: 2-hydrazino-1-phenylpropane]. GENOVESE E; ARRIGONI-MARTELLI E; FRESIA P Farmaco Sci; 1959 Jul; 14():516-26. PubMed ID: 13849925 [No Abstract] [Full Text] [Related]
13. Monoamine oxidase inhibitors. II. Some amino and dialkylaminobenzyl hydrazines and their acyl derivatives. GARDNER TS; WENIS E; LEE J J Med Pharm Chem; 1961 Mar; 3():241-52. PubMed ID: 13896916 [No Abstract] [Full Text] [Related]
14. Monoamine oxidase inhibitors. I. 1-Alkyl and 1-aralkyl-2-(picolinoyl and 5-methyl-3-isoxazolyl-carbonyl)hydrazines. GARDNER TS; WENIS E; LEE J J Med Pharm Chem; 1960 Apr; 2():133-45. PubMed ID: 13826540 [No Abstract] [Full Text] [Related]